Allogene Therapeutics
Geoffrey Parker serves as Executive Vice President and Chief Financial Officer at Allogene Therapeutics since October 2023. Parker is a Board Member at Better Therapeutics and Perrigo Company plc, holding these positions since April 2021 and November 2016, respectively. Previously, Parker was the Chief Operating Officer, Chief Financial Officer, and Executive Vice President at Tricida, Inc. until June 2023, and served on the boards of several other companies, including ChemoCentryx, Inc., Genomic Health, Sunesis Pharmaceuticals, and Genoptix, Inc. In addition, Parker was the Executive Vice President and Chief Financial Officer at Anacor Pharmaceuticals, leading the company from pre-IPO to a market capitalization exceeding $3 billion. With a decade-long career in investment banking at Goldman Sachs, Parker managed the healthcare investment banking team and executed significant transactions valued over $100 billion. Parker holds an MBA from Stanford University and a double major in Economics and Engineering Sciences from Dartmouth College.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.